ATC Group: H01CB02 Octreotide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H01CB02 in the ATC hierarchy

Level	Code	Title
`1`	H	Systemic hormonal preparations, excl. Sex hormones and insulins
`2`	H01	Pituitary and hypothalamic hormones and analogues
`3`	H01C	Hypothalamic hormones
`4`	H01CB	Somatostatin and analogues
`5`	H01CB02	Octreotide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
PAREN	Parenteral	0.7 mg

Active ingredients in H01CB02

Active Ingredient
Octreotide
Octreotide is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects, but with a considerably prolonged duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the GEP endocrine system.

Related product monographs

Document	Type	Information Source
MYCAPSSA Gastro-resistant hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)
OLATUTON Powder and solvent for suspension for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
SANDOSTATIN LAR Powder and solvent for suspension for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
SANDOSTATIN Solution for injection	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)